Figure 3.

Recombinant human transforming growth factor β1 (rhTGFβ1) treatment alters protein levels of phospho-Smad1/5/8, Smad1, TGFβ receptor (TGFβR) and Ski-related novel protein N (SnoN) in primary human osteoblasts. (A) Representative western blot picture of primary human osteoblasts treated with 50 ng/ml recombinant human bone morphogenic protein (rhBMP)-2 or rhBMP-7 ± 5 ng/ml rhTGFβ1 for 72 h. Membranes were probed for phospho-Smad1/5/8, Smad1/2, TGFβR and SnoN. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. Densitometric analysis (N = 6; n = 6) for (B) phospho-Smad1/5/8, (C) Smad1, (D) TGFβR and (E) SnoN. *P < 0.05; **P < 0.01; ***P < 0.001 as compared to untreated cells. °°P < 0.01; °°°P < 0.001.

Ehnert et al. BMC Medicine 2012 10:101   doi:10.1186/1741-7015-10-101
Download authors' original image